The US Food and Drug Administration (FDA) approved secukinumab (Cosentyx/Novartis) for adults with moderate to severe plaque psoriasis.
The European Commission approved the same drug on Jan. 19. Its active ingredient is an antibody that binds to interleukin-17A and interferes with inflammation. The binding prevents that protein from triggering the inflammatory response that results in psoriasis patches.
Study shows ustekinumab more effective at certain doses and in treatment-naïve patients. Several factors associated with diminished treatment response also identified.
A trio of phase 3 trials will evaluate the safety and efficacy of certolizumab pegol evaluated for the treatment of adults with moderate-to-severe chronic plaque psoriasis.
A round up of recent research results on plaque psoriasis treatment with itolizumab, apitherapy, and ponesimod.
Cosentyx (secukinumab) has been approved in Japan for the treatment of psoriasis vulgaris (also known as plaque psoriasis) and psoriatic arthritis.
Psoriasis is associated with a higher risk of developing chronic kidney disease and glomerulonephritis, according to a study published online Dec. 15 in the British Journal of Dermatology.